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Background. There is little information on multiple human papillomavirus (HPV) infections and the potential
for type competition in men, yet competition may impact the type-specific efficacy of HPV vaccination.
Methods. Among 2702 uncircumcised men in Kisumu, Kenya, who were seronegative for human
immunodeficiency virus, the observed numbers of HPV types detected were compared with the expected number,
which was simulated under the assumption of independent infections. To assess the potential for HPV type
competition, adjusted odds ratios for pairwise combinations of prevalent HPV type infections were estimated using
semi-Bayesian methods.
Results. Half of all men were HPV positive, of whom 57% had multiple HPV types. We observed men without
HPV infection and with $4 HPV types more often than expected if infections were independent. No negative
associations between individual HPV types were observed. HPV types 31, 39, 56, 58, and 59 were positively
associated with both carcinogenic vaccine types HPV-16 and HPV-18 (2-sided P value ,.05).
Conclusions. Men who were HPV infected were likely to test positive for .1 HPV type. Cross-sectional
associations between individual HPV types were positive and did not appear to be type-specific. Thus, we did not
identify HPV types that are candidates for potential HPV type competition in men.
Human papillomavirus (HPV) infection is themain cause
of cervical cancer in women [1, 2] and is responsible for
other genital cancers, including anal and penile carcinoma
in men. Coinfection with multiple HPV types is common
and observed in 20%–73% of HPV-infectedmales [3–11].
Multiple HPV-type infections have been associated with
acquisition of other HPV types and increased HPV per-
sistence in men [7] and cervical precancerous lesions in
women [12–14].
There are currently 2 FDA-approved HPV vaccines
that provide protection against HPV-16 and 18 [15–17]
or HPV-16, 18, 6, and 11 [18–20]. Nearly 70% of cases of
cervical cancer have been attributed to infection with
oncogenic HPV types 16 and 18 [21, 22], and low-risk
HPV types 6 and 11 are responsible for 90% of genital
warts. HPV-type coinfections could affect the pop-
ulation-based impact of HPV vaccination in both young
women and men due to potential HPV type competition
and subsequent type replacement [23, 24], that is, an
increase in the prevalence of nonvaccine HPV types in the
population when vaccine-preventable HPV types are re-
duced or eliminated [25]. Type competition may result
from some yet unknown biological mechanism, whereby
infection with 1 HPV type inhibits the acquisition or
persistence of other HPV types [7, 26]. In contrast, if
infection with a specific HPV type facilitates the acqui-
sition or persistence of other HPV types, it is possible that
when 1 HPV type is prevented by vaccination, the other
type might be reduced in the population.
If HPV types do compete, this will be reflected in
the population as a low probability of coinfection with
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2 specific HPV types. However, there are several reasons why, in
addition to the possibility of type competition, that 2 HPV types
may be less likely to occur together within a multiple infection.
The prevalence of HPV types detected in a sample population are
dependent on the HPV type distribution in the general pop-
ulation in that geographical area, as well as the HPV types cir-
culating within individual networks of sexual contacts. In
addition, observed positive associations between HPV types may
be due to the common transmission route and risk factors for all
HPV types, such as age [25, 27, 28], condom use [9], circumci-
sion status [6, 11], and lifetime [9, 29, 30] or recent [28] number
of sexual partners. Thus, any association between individual HPV
types reflects a combination of exposure to HPV, the type dis-
tribution among sexual contacts, and host immunological and
behavioral characteristics [7, 26, 31].
To date, there are no detailed studies of multiple HPV in-
fections and type competition in an African population, where
the HPV genotype distribution may differ from those in North
America, Europe, or South America [32]. Given the recent
approval of HPV prophylactic vaccination in the United States
for young men [33], data on HPV coinfections in men and
their female sexual partners are needed to assess the potential
for future HPV type replacement. We previously reported the
risk factors for HPV infection [3], prevalence by HPV stratified
by penile site [34], and association between HPV infection and
the risk of human immunodeficiency virus (HIV) acquisition
[35] among men from Kisumu, Kenya, participating in a ran-
domized controlled trial (RCT) of male circumcision [36]. In
the present analysis, we investigated the associations between
vaccine-preventable HPV types (16, 18, 6, and 11) and 41 other
HPV types using semi-Bayesian methodology.
METHODS
Study Population and Design
From February 2002 to December 2006, an RCT was conducted
in Kisumu, Kenya, to determine the effectiveness of male cir-
cumcision in reducing HIV incidence [36]. Male participants
were recruited from sexually transmitted infection (STI) clinics,
workplaces, and community organizations. To be included in the
RCT, men were required to be 18–24 years of age, uncircumcised,
HIV-seronegative, and sexually active and to have a hemoglobin
level of $90 g/L.
An observational cohort study of the effect of circumcision
on the natural history of penile HPV infection was nested in the
RCT [3, 34, 35]. The present analysis is a cross-sectional study at
the baseline visit of uncircumcised, HIV-seronegative men who
were eligible for participation in the main RCT (n 5 4489) and
consented to HPV testing (n5 2705) [3]. In the present analysis,
3 men were excluded due to inconsistent records in the database.
The final population for this analysis includes 2702 men who
provided penile samples and information on sexual risk factors
at baseline, of which 2228 were enrolled in the RCT. The study
protocol was approved by the institutional review boards at all
collaborating institutions.
Medical Examination and Sample Collection
After participants provided informed consent, trained male in-
terviewers administered a standardized questionnaire on socio-
demographic characteristics, medical conditions, and sexual
behavior. A trained physician or clinical officer conducted
a physical exam during which a genital examination was con-
ducted to inspect for ulcers and warts. Blood was collected for
herpes simplex virus type 2 (Kalon Biological) and syphilis testing
(Becton Dickinson; rapid plasma reagin with Treponema pallidum
hemagglutination assay confirmation). Urine samples were col-
lected for polymerase chain reaction (PCR) detection of Neisseria
gonorrhoeae and Chlamydia trachomatis (Roche Diagnostics).
Exfoliated penile cells were collected from 2 anatomical sites
using 2 prewetted Dacron swabs: (1) shaft and external foreskin
tissue (shaft specimen) and (2) glans, coronal sulcus, and inner
foreskin tissue (glans specimen) [34]. The penile swabs were
placed in separate 15-mL tubes containing 2-mL of Tris buffer
0.01 mol/L and processed on the day of collection. All samples
were sent to theDepartment of Pathology at the Vrije Universiteit
University Medical Center for laboratory detection of HPVDNA.
Detection of HPV DNA
Laboratory Detection
HPV DNA testing was performed on uncircumcised men at the
baseline study visit. DNA was isolated from exfoliated penile cell
samples [37, 38], and the presence of human DNA was evaluated
by b-globin–specific PCR, followed by agarose gel electrophoresis.
The presence of HPV DNA was assessed by GP51/61 PCR,
followed by hybridization of PCR products using an enzyme im-
munoassay readout with 2 HPV oligoprobe cocktails that together
detect 44 HPV types. Subsequent HPV genotyping was performed
by reverse line blot hybridization (RLBH) of PCR products, as
described elsewhere [37, 38]. HPV types 16, 18, 31, 33, 35, 39, 45,
51, 52, 56, 58, 59, 66, and 68 were classified as high-risk (carci-
nogenic) HPV (HR-HPV) types. Low-risk (LR-HPV) types in-
cluded 6, 11, 26, 30, 32, 34, 40, 42, 43, 44, 53, 54 55, 57, 61, 64, 67,
69, 70, 71 (equivalent to CP8061), 72, 73, 81 (CP8304), 82 (IS39
and MM4 subtypes), 83 (MM7), 84 (MM8), 85 (cand85), 86, 89
(cand89 equivalent to CP6108), and JC9710. Types considered
vaccine preventable were HPV-16, 18, 6, and 11, whereas all others
were nonvaccine preventable HPV types. HPV types detected by
PCR but not genotyped were designated as HPV-X, indicating
a type, subtype, or variant undetectable with RLBH probes.
Definition of Multiple Infections
HPV DNA detection methods were carried out on the shaft
and glans samples separately. Given that the aims of the present
analyses relate to evaluating the potential for HPV type re-
placement following population-based HPV vaccination and
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not site-specific infection, we present pooled HPV results for the
shaft and glans specimens. A single infection is defined as HPV
DNA positivity to any 1 single HPV type in the glans, the shaft,
or both sites. A multiple infection is defined as the detection of
$2 different HPV types in either the glans or the shaft com-
bined. For example, if a man was HPV-16 positive in the shaft
and HPV-35 positive in the glans, or if a man was HPV-16 and
HPV-35 positive in the glans and HPV negative in the shaft,
the man was classified as having multiple infections. If HPV-X
occurred alone, the infection was classified as a single infection,
although it could represent.1 untyped HPV infection. If HPV-X
was detected with additional typed infections, the infection was
classified as a multiple HPV infection.
Statistical Analysis
Distribution of Number of HPV Genotypes
The observed number of men with 0, 1, 2, 3, 4, 5, and 6 or more
concurrent HPV type infections was compared to the frequency
that would be expected under the assumption that each HPV
infection is independent of all others. Infection with each of the
45 possible HPV types was simulated for each man by random
generation of a binary variable with the probability of infection
equal to the observed prevalence of that type in the study pop-
ulation. Expected frequencies for each number of concurrent
HPV infections were calculated as the average frequency over
1000 stochastic simulations of 2702 observations [26]. For HR-
HPV simulations, the observed probabilities of the 14 HR-HPV
types were used to simulate the expected number of infections
with only HR-HPV types. As done elsewhere [3], all analyses
included males who were HPV positive regardless of b-globin
positivity and were conducted using SAS software, version 9.2
(SAS).
Correlates of Multiple HPV Infections
Univariate logistic regression was used to estimate odds ratios
(ORs) and 95% confidence intervals (CIs) for potential correlates
of multiple versus single HPV infections. Variables were identified
a priori as potential correlates of multiple HPV infection based on
the previous literature [3, 7, 9]. Multivariate logistic regression
was used to estimate associations between each potential correlate
and multiple HPV infections, simultaneously adjusting for all
other potential correlates.
HPV Type Associations in Multiple Infections
We used hierarchical regression analysis to obtain semi-Bayesian
estimates of the ORs [39] between the 4 vaccine-preventable HPV
types and 41 other outcome HPV types, adjusting for the po-
tential correlates of multiple HPV infections. Shrinkage methods,
such as the one we used here, reliably reduce the overall error in
the ensemble of estimates and enhance the precision of each
estimate by incorporating prior information from the study
data [40, 41]. HPV-16, 18, 6, and 11 type-specific prior means,
lj, where j 5 1–4, were estimated from the data, and their vari-
ability was propagated through hyperpriors. The lj are the av-
erage of the log OR between the individual vaccine type and
all 41 other HPV types, adjusted for age, travel to Nairobi
(in 6 months prior to baseline), bathing frequency, number of
sexual partners (in the 6 months prior to baseline), consistent
condom use (in the 6 months prior to baseline), and current
N. gonorrhoeae and C. trachomatis infections. The prior vari-
ance for each lj, s
2, was set equal to 0.17 because we assumed
that 95% of the log ORs should fall within a 5-fold range based
on previous literature [24, 26, 31, 42, 43], which corresponds to
a variance of [ln(5)/3.92]2 5 0.17.
Model estimates are reported as the exponentiated poste-
rior medians and 95% credible intervals, analogous to ad-
justed odds ratios (AORs) and corresponding 95% CIs.
Potential evidence of HPV type nonindependence is an AOR
estimate ,1.0: the odds of a nonvaccine-preventable type are
lower in men with a vaccine-preventable HPV type compared
with men without a vaccine-preventable type.
Sensitivity Analysis
The case of thebivalentHPVvaccinewas also considered; analyses
were conducted as outlined above, except HPV-16 and 18 were
considered exposure types, and the 43 other types, including
HPV-6 and 11, were considered outcome types. Further, we ex-
plored results obtained when setting s2 to 0.35 or 1.38, reflecting
a 10- and 100-fold prior 95% confidence limit. For comparison,
maximum likelihood estimates of HPV type associations are also
presented (Supplementary Table 1).
RESULTS
Among 2702 men, with a median age of 20 years (range, 17–28),
51% were HPV positive (n 5 1379). A single HPV type was
detected in 22% (n 5 592) and multiple HPV types were de-
tected in 29% (n 5 787) of men. The 5 most prevalent types
overall were HPV-16 (n 5 263; 10%), HPV-X (n 5 164; 6%),
HPV-56 (n 5 164; 6%), HPV-42 (n 5 140; 5%), and HPV-67
(n 5 139; 5%). The 5 most prevalent types within multiple
infections were HPV-16 (n 5 196; 25%), HPV-56 (n 5 135;
17%), HPV-42 (n 5 120; 15%), HPV-67 (n 5 117; 15%), and
HPV-52 (n 5 116; 15%) (Figure 1). All HPV types were more
likely to be detected as multiple infections rather than single
infections, with the exception of HPV-X, which was less likely
to be detected in the presence of other typed HPV infections
(37% multiple infections, 63% single infections).
The number of HPV types detected within an individual
ranged from 0 to 11 infections. The observed frequency of zero
HPV infections and infections with 4, 5, and 6 or more HPV
types were higher than expected under the assumption that in-
fections are independent (2-sided P value ,.01) (Table 1).
Frequencies of 1 or 2 HPV types were less than expected
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(P , .01). The distribution of observed high-risk genotype in-
fections was similar to infection with any HPV genotype.
Multiple HPV infections were more common among men who
were younger, bathed less often than daily, and had chlamydial
infection. Men were less likely to have multiple versus single HPV
type infections if they were older, or reported consistent condom
use in the previous 6 months (Table 2). The strongest in-
dependent positive correlate of multiple HPV infections was
bathing less often than daily (AOR, 2.1 [95% confidence interval,
1.0–4.4] vs daily bathing). In contrast, men who reported always
using a condom in the previous 6months had a 30% lower odds of
multiple HPV infections (AOR, 0.7 [0.5–0.9] vs inconsistent users).
In the main analysis using semi-Bayesian logistic regression,
there were no negative associations between the 4 vaccine-
preventable HPV types (HPV-16, 18, 6, and 11) and the other
41 HPV types (AORs .1.0; Table 3). Although a few negative
Figure 1. Human papillomavirus (HPV) genotype distribution of single and multiple infections, in order of descending prevalence.
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associations were observed in the semi-Bayesian models with
less precision and in the maximum likelihood models, all
confidence intervals were wide and included the null value 1.0
(Supplementary Table 1). There was no clear pattern of dif-
ferences in HPV type associations within or across HPV clades.
HPV-16 was positively associated with 17 of the 41 nonvaccine
HPV types (range of AORs, 1.7–3.6). Men with HPV-16
infection were 3.6 times as likely to also be infected with HPV-
40 compared with men without HPV-16 infection (Table 3;
AOR, 3.6 [2.4–5.2]). HPV-18 was positively associated with 33
nonvaccine types (range of AORs, 1.8–4.3) and had the
strongest association with HPV-26 (AOR, 4.3 [2.1–7.7]). For
the vaccine-preventable low-risk types 6 and 11, 12 nonvaccine
HPV types were positively associated with HPV-6, and 14 HPV
Table 1. Comparison of the Observed and Expected Number of Human Papillomavirus Types Detected
No. of HPV Genotypes
Any HPV HR-HPV
Observed Expected P Valuea Observed Expected P Valuea
0 1323 832.9 ,.01 1749 1494.3 ,.01
1 592 1002.1 ,.01 571 909.4 ,.01
2 349 581.1 ,.01 230 251.5 .15
3 194 214.6 .15 103 41.6 ,.01
4 111 57.3 ,.01 34 4.8 ,.01
5 68 11.9 ,.01 11 0.4 ,.01
$6 65 2.2 ,.01 4 0.0 ,.01
Mean (SD) 1.15 (1.60) 1.15 (1.05) 0.58 (0.96) 0.58 (0.74)
Abbreviation: HR-HPV, high-risk human papillomavirus.
a Two-sided P-value calculation: For i 5 0–61 types, let Oi be the observed number of men with i infections and let Ei be the expected number of men with i
infections (based on 1000 simulations) assuming independence. For simulated data sets j 5 1–1000, let Oij be the number of men with i infections. Then for
i 5 0–61 types, the 2-sided P value was calculated as proportion of simulated data sets where jOij-Eij.5 jOi-Eij.
Table 2. Correlates Multiple Human Papillomavirus (HPV) Infections Among 1379 Men With HPV Infection at Baselinea
Single HPV Multiple HPV Unadjusted OR (95% CI) Adjusted OR (95% CI)b
Median (IQR) Age, years 21 (19–22) 20 (19–22) 0.9 (.9–1.0) 0.9 (.9–1.0)
Recent travel to Nairobic
No 480 (81.4) 670 (85.5) ref ref
Yes 110 (18.6) 114 (14.5) 0.7 (.6–1.0) 0.7 (.5–1.0)
Bathing frequency
Daily 571 (97.6) 751 (96.3) ref ref
Less than daily 14 (2.4) 29 (3.7) 1.6 (.8–3.0) 2.1 (1.0–4.4)
Recent no. of sexual partnersc
0–1 330 (56.2) 417 (53.1) ref ref
$2 257 (43.8) 369 (47.0) 1.1 (.9–1.4) 1.1 (.9–1.4)
Recent condom usec
Not always 410 (76.2) 590 (82.9) ref ref
Always 128 (23.8) 122 (17.1) 0.7 (.5–0.9) 0.7 (.5–0.9)
Neisseria gonorrhoeae
No 565 (98.1) 754 (96.7) ref ref
Yes 11 (1.9) 26 (3.3) 1.8 (.9–3.6) 1.9 (.9–4.2)
Chlamydia trachomatis
No 551 (95.8) 723 (92.7) ref ref
Yes 24 (4.2) 57 (7.3) 1.8 (1.1–3.0) 1.7 (1.0–2.8)
Missing data: Travel to Nairobi in 6 months prior to baseline (n5 5), bathing frequency (n5 14), number of sexual partners in 6 months prior to baseline (n5 6), condom
use in 6 months prior to baseline (men reporting no sex in last 6 months included in ‘‘always’’ category; (n 5 129), N. gonorrhoeae (n 5 23), C. trachomatis (n 5 24).
Abbreviations: CI, confidence interval; HPV, human papillomavirus; IQR, interquartile range; ref, reference category for the odds ratio.
a Data are numbers (%) unless otherwise specified.
b Estimates are adjusted for all potential correlates.
c In the previous 6 months.
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Table 3. Estimated Odds Ratios Between the 4 Vaccine-Preventable Human Papillomavirus (HPV) Types and All Other Nonvaccine HPV
Types Among All Men
HPV-16, AOR (95% CI)a HPV-18, AOR (95% CI)a HPV-6, AOR (95% CI)a HPV-11, AOR (95% CI)a
Clade A3
HPV-61 2.2 (.9–4.5) 2.7 (1.1–5.5) 2.0 (.8–4.0) 2.3 (.9–4.7)
HPV-72 2.7 (1.3–4.8) 2.6 (1.2–4.9) 1.8 (.8–3.4) 2.7 (1.2–5.2)
HPV-81 1.7 (1.0–2.8) 2.4 (1.2–4.0) 2.8 (1.5–4.7) 1.8 (.8–3.3)
HPV-83 1.8 (.9–3.0) 2.8 (1.4–5.0) 1.9 (.9–3.5) 2.6 (1.2–4.8)
HPV-84 1.8 (.8–3.4) 2.2 (1.0–4.3) 1.8 (.8–3.5) 2.1 (.9–4.3)
HPV-89 1.7 (1.0–2.9) 2.5 (1.3–4.2) 1.5 (.7–2.8) 1.9 (.9–3.5)
Clade A5
HPV-26 1.7 (.8–3.1) 4.3 (2.1–7.7) 1.7 (.8–3.3) 2.6 (1.1–5.1)
HPV-51 2.2 (1.4–3.4) 1.8 (1.0–3.1) 2.1 (1.1–3.6) 1.8 (.9–3.2)
HPV-69 2.5 (1.4–4.2) 2.8 (1.4–5.0) 1.9 (.9–3.6) 1.8 (.8–3.4)
HPV-82 1.5 (.7–2.7) 2.3 (1.0–4.3) 1.8 (.8–3.5) 2.7 (1.2–5.2)
Clade A6
HPV-53 2.6 (1.3–4.6) 2.3 (1.0–4.2) 1.8 (.8–3.4) 2.3 (1.0–4.5)
HPV-56 2.1 (1.4–3.0) 1.9 (1.1–2.9) 2.9 (1.8–4.3) 2.4 (1.3–3.9)
HPV-66 2.0 (1.3–3.0) 2.3 (1.3–3.5) 1.8 (1.0–2.9) 1.7 (.8–2.9)
Clade A7
HPV-39 2.1 (1.2–3.4) 2.2 (1.1–3.9) 2.0 (1.0–3.5) 2.4 (1.1–4.4)
HPV-45 1.7 (1.1–2.6) 2.9 (1.7–4.6) 2.0 (1.1–3.3) 2.8 (1.5–4.9)
HPV-59 2.3 (1.5–3.5) 2.9 (1.7–4.6) 1.7 (.9–2.9) 2.4 (1.2–4.2)
HPV-68 1.3 (.7–2.2) 2.1 (1.0–3.9) 1.6 (.7–2.9) 2.1 (.9–4.0)
HPV-70 1.6 (.9–2.6) 1.7 (.9–3.0) 1.3 (.6–2.4) 2.0 (1.0–3.8)
Clade A9
HPV-31 2.9 (1.9–4.2) 2.8 (1.6–4.4) 1.6 (.8–2.7) 1.8 (.9–3.2)
HPV-33 1.9 (1.0–3.1) 2.6 (1.3–4.5) 1.4 (.7–2.6) 2.5 (1.1–4.6)
HPV-35 2.5 (1.6–3.7) 1.9 (1.1–3.1) 2.4 (1.4–3.9) 2.0 (1.0–3.4)
HPV-52 1.7 (1.1–2.5) 2.3 (1.3–3.6) 3.4 (2.1–5.3) 1.9 (1.0–3.3)
HPV-58 2.6 (1.7–3.9) 2.3 (1.3–3.6) 1.7 (.9–2.8) 1.9 (.9–3.2)
Clade A10
HPV-44 2.1 (.9–4.2) 2.7 (1.1–5.5) 2.0 (.8–4.0) 2.3 (.9–4.6)
HPV-55 1.5 (.8–2.6) 2.0 (1.0–3.5) 2.6 (1.3–4.5) 2.6 (1.2–4.8)
Clade A11
HPV-34 2.0 (.9–4.0) 3.1 (1.3–6.3) 2.0 (.8–4.1) 2.3 (.9–4.6)
HPV-64 2.1 (.9–4.2) 2.7 (1.1–5.5) 2.0 (.8–4.0) 2.3 (.9–4.6)
HPV-73 2.2 (1.2–3.5) 3.0 (1.6–5.1) 2.0 (1.0–3.6) 2.3 (1.1–4.2)
Other
HPV-30 1.7 (.9–2.9) 3.1 (1.5–5.3) 1.7 (.8–3.1) 2.3 (1.0–4.3)
HPV-32 1.7 (.9–2.9) 2.3 (1.1–4.0) 2.4 (1.2–4.3) 2.3 (1.0–4.3)
HPV-40 3.6 (2.4–5.2) 2.2 (1.3–3.5) 2.0 (1.1–3.3) 2.4 (1.2–4.2)
HPV-42 2.1 (1.4–3.0) 2.3 (1.3–3.6) 2.0 (1.2–3.2) 2.6 (1.4–4.4)
HPV-43 1.7 (1.1–2.6) 2.3 (1.3–3.7) 3.0 (1.7–4.8) 2.0 (1.0–3.6)
HPV-54 1.4 (.7–2.6) 2.6 (1.2–4.7) 1.8 (.8–3.4) 2.0 (.9–3.9)
HPV-57 2.2 (.9–4.5) 2.7 (1.1–5.5) 2.0 (.8–4.0) 2.3 (.9–4.7)
HPV-67 2.4 (1.6–3.4) 1.8 (1.1–2.9) 2.6 (1.5–4.1) 2.0 (1.0–3.5)
HPV-71 2.2 (0.9–4.5) 2.7 (1.1–5.5) 2.0 (.8–4.0) 2.3 (.9–4.7)
HPV-85 2.0 (.9–3.8) 2.8 (1.2–5.6) 2.1 (.9–4.3) 2.2 (.9–4.5)
HPV-86 1.8 (.9–3.4) 3.2 (1.5–6.1) 1.7 (.7–3.2) 2.4 (1.0–4.7)
HPV-JC9710 1.8 (1.1–2.6) 2.8 (1.7–4.3) 1.5 (.8–2.5) 2.1 (1.1–3.7)
HPV-X 1.2 (.8–1.8) 1.7 (1.0–2.7) 1.7 (1.0–2.7) 1.3 (.6–2.3)
Abbreviations: AOR, adjusted odds ratio; CI, confidence interval.
a ORs for pairwise associations are adjusted for age, travel to Nairobi (in previous 6 months), bathing frequency, number of sexual partners (in previous 6 months),
consistent condom use (in previous 6 months), and current Neisseria gonorrhoeae and Chlamydia trachomatis infection.
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types were positively associated with HPV-11. HPV-52 was
most strongly associated with HPV-6 (AOR, 3.4 [2.1–5.3]), and
HPV-45 was most strongly associated with HPV-11 (AOR, 2.8
[1.5–4.9]). Results from models including only HPV-16 and
HPV-18 as the vaccine-preventable types were almost identical to
the 4 vaccine type models (Supplementary Table 2). Additional
positive associations between low-risk types HPV-6 and HPV-11
with HPV-16 and HPV-18 were observed. When analyses were
restricted to HPV-positive men, point estimates tended to be
closer to the null, and HPV type associations appeared not to
differ within or across HPV clades (Table 4). HPV-40 (AOR, 2.1
[1.4–2.9]) and HPV-26 (AOR, 3.4 [1.7–5.8] remained the HPV
types most strongly associated with HPV-16 and HPV-18,
respectively.
DISCUSSION
Half of all uncircumcised, HIV-negative men in this study from
Kenya were infected with at least 1 HPV type at baseline. Nearly
30% of surveyed men had multiple penile HPV type infections,
with HPV-16 and 18 accounting for .25% of all infections. If
prevalent carcinogenic HPV-16 and 18 infections were prevented
by mass vaccination, there is a theoretical possibility that this
could result in other HR-HPV types filling the ecological niche of
HPV-16 and/or 18 [44]. Because there are reported differences in
genotype distributions across sexes and geographical regions
[5, 32, 45], the potential for HPV type replacement could differ
across study populations. The present study represents, to our
knowledge, the first detailed investigation of multiple HPV in-
fections and type associations within a cohort of young men from
Africa. Using a cross-sectional study design, we did not find any
negative associations between vaccine-preventable types HPV 16,
18, 6, and 11, and 41 nonvaccine-preventable HPV types.
All HPV genotypes were more likely to be detected as multiple
rather than single-type infections. Further, all associations be-
tween HPV types were positive, suggesting that men who be-
come infected are more likely to have .1 HPV infection,
possibly due to host behavioral or immunological factors [7, 26,
31]. When analyses were restricted to HPV-infected men, as-
sociations between specific HPV types generally shifted closer
toward 1.0, which suggests that specific HPV types are not as-
sociated with one another. We also observed a higher number of
men than expected with $4 HPV type infections, suggesting
that individual HPV infections were not independent from each
other. This is likely due to the fact that men with $4 HPV
infections reported less condom use in the last 6 months and
more lifetime partners than did men with fewer HPV infections.
These observations inmen are consistent with results from studies
among women [42, 46, 47]. Numerous prospective studies have
found that women with HPV infection at baseline are more likely
to acquire additional HPV types [7, 23, 26, 31, 43] and that
acquisition of multiple HPV types occurs more often than
expected [7, 24, 26]. Therefore, it is likely that the observed
pattern of number and types of HPV infections reflect differences
in HPV persistence or acquisition in men with multiple in-
fections.
Positive associations between HPV types were observed yet
appeared not to be type-specific. Our results among Kenyan
men are consistent with a prospective study of American female
college students that found no 2 HPV types are more likely to be
acquired together than any other HPV types [26]. Most studies
that have examined HPV type associations in women have re-
ported positive or no associations between HPV types, regard-
less of the pairwise combinations, analytical methods, HPV
genotyping methods, or study population [26, 46]. However,
among female colposcopy clinic attendees in Italy, where the ge-
notype distribution likely differs compared to the general pop-
ulation, coinfection with species A7 and A10 and with HPV-31
and 52 occurred less often than expected [48]. A large cross-
sectional study of Danish women referred for testing based on
clinical suspicion of infection found that HPV-51 was negatively
associated with HPV-16 [42].
In this large sample of men with an HPV prevalence of 50%,
we examined type-type associations, even for rarer HPV types,
using semi-Bayesian methods that incorporated a shrinkage
factor. We chose shrinkage methods because they allowed us to
include all 4 vaccine types and numerous potential confounders
in each model. In addition, these methods serve as an adjust-
ment for multiple comparisons [49] and reduce the number of
spurious associations as compared with maximum likelihood
methods [50]. There is, however, a trade-off between precision
and bias in methods that incorporate a shrinkage factor [40].We
therefore conducted sensitivity analyses to understand the effect
of our statistical model choices and to compare our results with
other studies that used maximum likelihood estimation [42, 46,
47]. Different methods to analyze our data resulted in wider
confidence intervals and, in some cases, nonsignificant ORs
,1.0. However, all methods resulted in the same conclusions
regarding the lack of evidence of negative associations between
prevalent HPV type infections in men. As in previous studies
[42, 46–48], we made multiple comparisons across outcomes,
which can increase the possibility of falsely concluding that
certain HPV types are associated. By including all 4 vaccine types
in each of our models, the number of comparisons was reduced
compared with other pairwise analyses [24, 42, 43, 46, 47].
In the present study, we could only determine if the number
and type of HPV infections were independent. The causes of
nonindependence may be differences in host susceptibility,
the distribution of HPV genotypes among female sexual
partners, primer competition during PCR detection, or mo-
lecular interactions between HPV types that inhibit infection
with other HPV types (type competition). Although we were
able to control for several measured confounders, it is likely
that there is residual confounding by other unmeasured
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Table 4. Estimated Odds Ratios Between the 4 Vaccine-Preventable Human Papillomavirus (HPV) Types and All Other Nonvaccine HPV
Types Among Men With at Least 1 HPV Infection
HPV-16, AOR (95% CI)a HPV-18, AOR (95% CI)a HPV-6, AOR (95% CI)a HPV-11, AOR (95% CI)a
Clade A3
HPV-61 2.1 (.9–4.4) 2.8 (1.1–5.8) 2.1 (.8–4.2) 2.3 (1.0–4.8)
HPV-72 2.1 (1.0–3.6) 2.3 (1.1–4.3) 1.6 (.7–3.1) 2.4 (1.1–4.7)
HPV-81 1.1 (.7–1.8) 1.7 (.9–2.8) 2.0 (1.1–3.3) 1.5 (.7–2.6)
HPV-83 1.2 (.7–2.0) 2.1 (1.1–3.7) 1.6 (.8–2.8) 2.2 (1.1–4.0)
HPV-84 1.5 (.7–2.7) 2.0 (.9–3.8) 1.6 (.7–3.0) 2.0 (.9–3.9)
HPV-89 1.2 (.7–1.8) 1.8 (1.0–3.0) 1.2 (.6–2.1) 1.6 (.8–2.8)
Clade A5
HPV-26 1.3 (.7–2.2) 3.4 (1.7–5.8) 1.5 (.7–2.8) 2.3 (1.1–4.4)
HPV-51 1.3 (.8–2.0) 1.3 (.7–2.1) 1.5 (.8–2.4) 1.4 (.7–2.4)
HPV-69 1.8 (1.0–2.8) 2.2 (1.1–3.7) 1.6 (.8–2.8) 1.6 (.7–2.9)
HPV-82 1.2 (.6–2.2) 1.9 (.9–3.6) 1.6 (.7–3.0) 2.4 (1.1–4.6)
Clade A6
HPV-53 1.9 (1.0–3.4) 1.9 (.9–3.5) 1.6 (.7–3.0) 2.1 (1.0–4.0)
HPV-56 1.2 (.8–1.6) 1.2 (.7–1.8) 1.8 (1.1–2.6) 1.7 (.9–2.7)
HPV-66 1.1 (.8–1.6) 1.5 (.9–2.2) 1.2 (.7–1.8) 1.2 (.6–2.1)
Clade A7
HPV-39 1.4 (.8–2.2) 1.7 (.9–2.9) 1.5 (.8–2.6) 2.0 (1.0–3.6)
HPV-45 1.1 (.7–1.6) 1.9 (1.1–3.0) 1.4 (.8–2.2) 2.1 (1.1–3.5)
HPV-59 1.4 (.9–2.1) 2.0 (1.2–3.1) 1.2 (.7–2.0) 1.8 (.9–3.1)
HPV-68 0.9 (.5–1.6) 1.7 (.8–2.9) 1.3 (.6–2.3) 1.8 (.8–3.2)
HPV-70 1.0 (.6–1.6) 1.3 (.7–2.2) 1.0 (.5–1.8) 1.7 (.8–3.0)
Clade A9
HPV-31 1.7 (1.1–2.4) 1.9 (1.1–3.0) 1.1 (.6–1.9) 1.4 (.7–2.4)
HPV-33 1.3 (.7–2.0) 1.9 (1.0–3.2) 1.2 (.6–2.1) 2.0 (1.0–3.6)
HPV-35 1.4 (.9–2.1) 1.3 (.8–2.1) 1.6 (1.0–2.5) 1.5 (.8–2.5)
HPV-52 1.0 (.6–1.4) 1.5 (.9–2.3) 2.1 (1.3–3.2) 1.4 (.8–2.5)
HPV-58 1.5 (1.0–2.2) 1.6 (.9–2.4) 1.2 (.7–1.9) 1.5 (.7–2.5)
Clade A10
HPV-44 2.0 (.8–4.1) 2.7 (1.1–5.5) 2.0 (.8–4.0) 2.3 (.9–4.8)
HPV-55 1.1 (.6–1.8) 1.5 (.8–2.7) 2.0 (1.0–3.4) 2.1 (1.0–3.9)
Clade A11
HPV-34 1.9 (.8–3.9) 3.1 (1.3–6.3) 1.9 (.8–3.8) 2.3 (.9–4.7)
HPV-64 2.0 (.8–4.1) 2.7 (1.1–5.5) 2.0 (.8–4.0) 2.3 (.9–4.8)
HPV-73 1.4 (.8–2.3) 2.2 (1.2–3.6) 1.6 (.8–2.6) 1.9 (.9–3.4)
Other
HPV-30 1.2 (.7–2.0) 2.3 (1.2–3.9) 1.4 (.7–2.4) 1.9 (.9–3.5)
HPV-32 1.2 (.7–2.0) 1.7 (.9–3.0) 1.9 (.9–3.2) 1.9 (.9–3.6)
HPV-40 2.1 (1.4–2.9) 1.6 (.9–2.5) 1.4 (.8–2.3) 1.8 (1.0–3.1)
HPV-42 1.2 (.8–1.7) 1.5 (.9–2.2) 1.3 (.8–2.0) 1.9 (1.0–3.0)
HPV-43 1.0 (.7–1.5) 1.5 (.9–2.4) 2.0 (1.2–3.0) 1.5 (.8–2.6)
HPV-54 1.1 (.6–2.0) 2.1 (1.0–3.9) 1.5 (.7–2.9) 1.8 (.8–3.4)
HPV-57 2.1 (.9–4.4) 2.8 (1.1–5.8) 2.1 (.8–4.2) 2.3 (1.0–4.8)
HPV-67 1.3 (.9–1.9) 1.2 (.7–1.9) 1.7 (1.0–2.5) 1.5 (.8–2.5)
HPV-71 2.1 (.9–4.4) 2.8 (1.1–5.8) 2.1 (.8–4.2) 2.3 (1.0–4.8)
HPV-85 1.8 (.8–3.4) 2.6 (1.2–5.2) 2.0 (.9–4.0) 2.1 (.9–4.2)
HPV-86 1.5 (.7–2.8) 2.7 (1.3–5.2) 1.5 (.7–2.9) 2.2 (1.0–4.3)
HPV-JC9710 1.0 (.7–1.5) 1.8 (1.1–2.7) 1.0 (.6–1.6) 1.6 (.8–2.6)
HPV-X 0.7 (.4–.9) 1.1 (.6–1.7) 1.1 (.6–1.6) 0.9 (.5–1.6)
Abbreviations: AOR, adjusted odds ratio; CI, confidence interval.
a ORs for pairwise associations are adjusted for age, travel to Nairobi (in previous 6 months), bathing frequency, number of sexual partner (in previous 6 months),
consistent condom use (in previous 6 months), and current Neisseria gonorrhoeae and Chlamydia trachomatis infection.
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behavioral risk factors, immunological differences between
men [7, 26], and HPV-type exposure from female sexual
partners. In populations where negative associations between
HPV types are observed, molecular studies and prospective
studies of couples are needed to address whether these asso-
ciations are likely due to true biological type competition or
competition for consensus primers.
Our study has additional limitations to consider when in-
terpreting the findings. We detected 103 single HPV-X in-
fections. If HPV-X represents multiple untyped infections, our
reported prevalence of multiple infections and the number of
HPV types detected are an underestimation. The likely impact of
untyped HPV infections on the conclusions regarding HPV-type
competition is minimal because inferences are mainly drawn
from type-specific analyses. In addition, the prevalence and the
type distribution of HPV has been shown to differ by circum-
cision status; thus, the results from this cohort of uncircumcised
men may not be generalizable to circumcised populations
[6, 11]. No participants received HPV prophylactic vaccination,
so we could only observe differences between individuals who
were naturally HPV uninfected and infected with HPV-16, 18, 6,
and 11. Given the cross-sectional design, it is also not known
whether infection with specific HPV types affects HPV acqui-
sition or HPV persistence of additional HPV types.
With the recent approval of HPV vaccination in men [33],
these data fill an important gap in our knowledge of the dis-
tribution and associations between HPV types in multiple in-
fections among men. Future prospective studies in populations
pre- and postvaccination are needed to observe the natural
history of multiple infections and assess the long-term potential
for HPV type replacement.
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